Acrodermatitis chronica atrophicans epidemiology and demographics: Difference between revisions
No edit summary |
(→Gender) |
||
| Line 27: | Line 27: | ||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | ||
===Gender=== | ===Gender=== | ||
*[ | *[[Acrodermatitis chronica atrophicans]] affects [[female|women]] more than [[male|men]].<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153 }} </ref> | ||
===Region=== | ===Region=== | ||
Revision as of 12:04, 2 June 2021
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics |
|
FDA on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
CDC on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Acrodermatitis chronica atrophicans epidemiology and demographics in the news |
|
Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics |
|
FDA on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
CDC on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Acrodermatitis chronica atrophicans epidemiology and demographics in the news |
|
Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
Race
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- Acrodermatitis chronica atrophicans affects women more than men.[1]
Region
- The majority of acrodermatitis chronica atrophicans cases are reported in northern, central and eastern Europe. [1]
- Lately few cases of acrodermatitis chronica atrophicans have been reported in the United States which were associated to Lyme disease (besides European immigrants). [1]
References
- ↑ 1.0 1.1 1.2 Khalili M, Wong RJ (2018). "Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net". Dig Dis Sci. 63 (12): 3250–3252. doi:10.1007/s10620-018-5316-9. PMC 6436636. PMID 30311153.